West Pharmaceutical Services INC (WST) — SEC Filings

Overview

West Pharmaceutical Services INC (WST) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Apr 23, 2026: West Pharmaceutical Services Inc. filed its quarterly report (10-Q) on April 23, 2026, for the period ending March 31, 2026. The filing includes financial statements and exhibits related to its operations. The company's mailing and business address is 530 Herman O. West Drive, Exton, PA 19341.

Sentiment Summary

Across 27 filings, the sentiment breakdown is: 2 bullish, 25 neutral. The dominant filing sentiment for West Pharmaceutical Services INC is neutral.

Filing Type Overview

West Pharmaceutical Services INC (WST) has filed 7 10-Q, 13 8-K, 1 8-K/A, 2 DEF 14A, 2 10-K, 2 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (27)

• West Pharmaceutical Services Files Q1 2026 10-Q — 10-Q · Apr 23, 2026 Risk: low
  West Pharmaceutical Services Inc. filed its quarterly report (10-Q) on April 23, 2026, for the period ending March 31, 2026. The filing includes financial state
• 8-K Filing — 8-K · Apr 23, 2026
• West Pharma Posts Strong Q3 Sales, Net Income Up 2.9% — 10-Q · Oct 23, 2025 Risk: medium
  WEST PHARMACEUTICAL SERVICES INC reported a robust financial performance for the three and nine months ended September 30, 2025. For the three-month period, net
• West Pharmaceutical Services Reports Director & Officer Changes — 8-K · Sep 11, 2025 Risk: medium
  On September 11, 2025, West Pharmaceutical Services, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangement
• West Pharma Soars on Biologics Demand, Q2 Revenue Up — 10-Q · Jul 24, 2025 Risk: low
  WEST PHARMACEUTICAL SERVICES INC (WST) reported a robust financial performance for the second quarter of 2025, with revenue from contract with customers for Bio
• West Pharmaceutical Services Files 8-K on Officer/Director Changes — 8-K · Jul 21, 2025 Risk: low
  On July 21, 2025, WEST PHARMACEUTICAL SERVICES, INC. filed an 8-K report. The filing pertains to the departure of directors or certain officers, the election of
• West Pharmaceutical Services Files 8-K/A Amendment — 8-K/A · May 12, 2025 Risk: low
  West Pharmaceutical Services, Inc. filed an 8-K/A on May 12, 2025, to amend a previous filing. The amendment pertains to Item 5.02, concerning the departure of
• West Pharmaceutical Services Holds Annual Stockholder Meeting — 8-K · May 8, 2025 Risk: low
  On May 6, 2025, West Pharmaceutical Services, Inc. filed an 8-K report to announce the results of its annual meeting of stockholders held on May 6, 2025. The co
• 10-Q Filing — 10-Q · Apr 24, 2025
• West Pharmaceutical Services Announces Leadership Changes — 8-K · Apr 14, 2025 Risk: medium
  On April 9, 2025, West Pharmaceutical Services, Inc. reported a departure of a director, Mr. David L. Johnson, who resigned from the Board of Directors. The com
• West Pharmaceutical Services Inc. Executive Compensation Filing — DEF 14A · Mar 21, 2025 Risk: low
  West Pharmaceutical Services Inc. filed its DEF 14A on March 21, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing
• West Pharmaceutical Services Reports Director & Officer Changes — 8-K · Mar 11, 2025 Risk: medium
  On March 7, 2025, West Pharmaceutical Services, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing incl
• West Pharmaceutical Services Files 2024 10-K — 10-K · Feb 18, 2025 Risk: medium
  West Pharmaceutical Services Inc. filed its 2024 10-K on February 18, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered in
• West Pharmaceutical Services Files 8-K — 8-K · Feb 13, 2025 Risk: low
  On February 13, 2025, WEST PHARMACEUTICAL SERVICES, INC. filed an 8-K report. The filing primarily concerns the company's results of operations and financial co
• West Pharmaceutical Services Files 8-K — 8-K · Dec 13, 2024 Risk: low
  On December 9, 2024, West Pharmaceutical Services, Inc. filed an 8-K report. The filing primarily concerns the submission of financial statements and exhibits.
• West Pharmaceutical Services Elects New Directors — 8-K · Dec 11, 2024 Risk: low
  On December 9, 2024, West Pharmaceutical Services, Inc. announced the election of two new directors, Dr. Steven A. Muchmore and Ms. Karen L. King, to its Board
• West Pharmaceutical Services Q3 2024 10-Q Filed — 10-Q · Oct 24, 2024 Risk: low
  West Pharmaceutical Services Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for
• West Pharmaceutical Services Reports Director and Officer Changes — 8-K · Oct 7, 2024 Risk: medium
  On October 1, 2024, West Pharmaceutical Services, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements.
• West Pharmaceutical Services Q2 2024 10-Q Filed — 10-Q · Jul 25, 2024 Risk: medium
  West Pharmaceutical Services Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the s
• West Pharmaceutical Services Secures $1.5B Credit Facility — 8-K · Jul 8, 2024 Risk: low
  On July 2, 2024, West Pharmaceutical Services, Inc. entered into a Material Definitive Agreement, specifically a Credit Agreement, with JPMorgan Chase Bank, N.A
• West Pharmaceutical Services CFO Departs; Director Changes — 8-K · Apr 26, 2024 Risk: medium
  On April 23, 2024, West Pharmaceutical Services, Inc. filed an 8-K report detailing several key events. The company announced the departure of its Chief Financi
• 10-Q Filing — 10-Q · Apr 25, 2024
• West Pharmaceutical Services Inc. Files Definitive Proxy Statement — DEF 14A · Mar 13, 2024 Risk: low
  WEST PHARMACEUTICAL SERVICES INC (WST) filed a Proxy Statement (DEF 14A) with the SEC on March 13, 2024. Filing is a Definitive Proxy Statement (DEF 14A) filed
• West Pharmaceutical Services Inc. Files 2023 Annual Report — 10-K · Feb 20, 2024 Risk: medium
  WEST PHARMACEUTICAL SERVICES INC (WST) filed a Annual Report (10-K) with the SEC on February 20, 2024. West Pharmaceutical Services Inc. filed its 10-K report f
• West Pharma Files 8-K for Financial Results and Disclosure — 8-K · Feb 15, 2024 Risk: medium
  WEST PHARMACEUTICAL SERVICES, INC. filed an 8-K on February 15, 2024, to report on its Results of Operations and Financial Condition. The filing also included a
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• BlackRock Amends West Pharma Stake, Signals Updated Position — SC 13G/A · Jan 24, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating its ownership of Common Stock in West Pharmaceutical Services Inc. as of December 31, 2

Risk Profile

Risk Assessment: Of WST's 22 recent filings, 0 were flagged as high-risk, 10 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from West Pharmaceutical Services INC's most recent 10-Q filing (Oct 23, 2025):

• Revenue: $804.6M
• Net Income: $140.0M
• EPS: $1.92
• Debt-to-Equity: N/A
• Cash Position: $628.5M
• Operating Margin: 20.8%
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Board of Directors
• David L. Johnson
• R. Sarah Keohane
• Kevin J. Cannon
• Dr. Steven A. Muchmore
• Ms. Karen L. King
• Bernard T. Young

Industry Context

West Pharmaceutical Services operates in the pharmaceutical packaging and delivery systems industry, a critical sector supporting global healthcare. The industry is characterized by stringent regulatory requirements, a focus on innovation for drug delivery, and increasing demand driven by an aging global population and advancements in biopharmaceuticals. Competition often centers on product quality, reliability, and technological capabilities in containment and delivery solutions.

Top Tags

10-Q (3) · financials (3) · corporate-governance (3) · compensation (3) · quarterly-report (2) · Pharmaceutical Services (2) · Medical Devices (2) · Earnings Growth (2) · executive-compensation (2) · officer-changes (2)

Key Numbers

• iXBRL 10-Q Size: 1263385 — Size of the main interactive data document.
• Complete submission text file Size: 8944591 — Total size of the complete submission text file.
• Net Sales (Q3 2025): $804.6M — Increased 7.7% from $746.9M in Q3 2024
• Net Income (Q3 2025): $140.0M — Increased 2.9% from $136.0M in Q3 2024
• Diluted EPS (Q3 2025): $1.92 — Increased from $1.85 in Q3 2024
• Net Sales (9 Months 2025): $2,269.1M — Increased 5.8% from $2,144.4M in 9 Months 2024
• Net Income (9 Months 2025): $361.6M — Slightly decreased from $362.6M in 9 Months 2024
• Cash and Cash Equivalents: $628.5M — Increased from $484.6M at Dec 31, 2024
• HVP Components Net Sales: 48% — Percentage of net sales for Q3 2025, up from 45% in Q3 2024
• Foreign Currency Translation Adjustments: $(12.0)M — Loss for Q3 2025, compared to $74.7M gain in Q3 2024
• Shares Purchased under Repurchase Programs: $134.0M — Total cost for 9 months ended Sept 30, 2025
• Property, Plant and Equipment, net: $1,740.6M — Increased from $1,581.6M at Dec 31, 2024
• Commission File Number: 1-8036 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 23-1210010 — Company's tax identification number.
• Biologics Revenue Q2 2025: $300M — Increased from $250M in Q2 2024, showing strong growth.

Related Companies

BDX · STE · ICLR

Frequently Asked Questions